AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin ...

With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...

In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.

Migraine prevention drugs are more targeted than ever before, and new guidelines may help doctors predict which will work for ...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and ...

Updated migraine guidance from the American Academy of Neurology and the American Headache Society includes both established ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

For chronic migraine, high-confidence evidence indicated patients had fewer headaches with fremanezumab, galcanezumab, and ...

AbbVie said its migraine drug met the primary and secondary endpoints in a phase 3 trial evaluating it for preventive treatment of menstrual migraines. The company on Thursday said the study showed ...

A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in ...

The updated guidelines, published in Neurology and Headache, include newer medicines that were not available when the earlier ...

Sept 10 (Reuters) - AbbVie said on Thursday its migraine treatment had in a late-stage study reduced the migraine days ...